Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gilead

- PMLiVE

Gilead and Galapagos close in on filing for Xeljanz rival

Belgian biotech gearing up for first approval

- PMLiVE

Janssen looks to expand Darzalex in Europe

Regimen reduced risk of disease progression or death by 44%

- PMLiVE

GSK’s myeloma drug hits target, prompting rapid filing pledge

Antibody drug conjugate could challenge CAR-Ts

- PMLiVE

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

Safety concerns could hit blockbuster expectations

- PMLiVE

NICE partially clears Darzalex combo in blood cancer

Approved in second-line use under  CDF

- PMLiVE

Riva leaves Gilead to head Glenmark’s innovation spin-off

Company has own bispecific antibody platform

- PMLiVE

AbbVie enters BCMA race with Teneobio deal

Agreement includes option to acquire TeneoOne

- PMLiVE

Gilead lead NASH drug flunks phase 3 test

Analysts suspect the setback could prompt Gilead to license other candidates

- PMLiVE

Gilead awaits CEO and readouts to revive fortunes

NASH and oral RA drugs set for crucial readouts

- PMLiVE

Sanofi’s Darzalex rival scores in myeloma trial

Antibody first to show benefit in combination setting

- PMLiVE

CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

Novartis agrees pricing deal with NHS England

- PMLiVE

Roche’s O’Day swaps big pharma for big biotech

Move to Gilead enforces reshuffle at neighbours Genentech

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links